Cullinan Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Cambridge, MA, June 16, 2026 – Cullinan Therapeutics, Inc. (“Cullinan” or “the Company”) has announced the results of its Annual Meeting of Stockholders held on June 16, 2026. The meeting included several important proposals, the outcomes of which may have implications for investors and could influence the Company’s share valuation.
Key Highlights from the Annual Meeting
- Election of Directors: Two Class III directors were elected to the Board for three-year terms, with both receiving significant shareholder support.
- Ratification of Independent Auditor: Stockholders ratified KPMG LLP as the Company’s independent registered public accounting firm for fiscal year 2026.
- Advisory Vote on Executive Compensation: Stockholders approved the compensation of Cullinan’s named executive officers in a non-binding advisory vote.
Detailed Voting Results
1. Election of Class III Directors
Shareholders voted to elect two directors to serve until 2029 or until their successors are duly elected and qualified:
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Nadim Ahmed | 12,116,759 | 4,126,430 | Not specified |
| Stephen Webster | 36,963,086 | 4,126,430 | Not specified |
Both directors received strong support, suggesting stability and continuity in the Company’s leadership. This may be viewed positively by investors seeking long-term strategic direction.
2. Ratification of KPMG LLP as Independent Auditor
| Votes For | Votes Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 53,722,477 | 36,815 | 0 | Not specified |
The overwhelming ratification of KPMG LLP reflects shareholder confidence in the Company’s financial reporting and audit process.
3. Advisory Vote on Executive Compensation (“Say on Pay”)
| Votes For | Votes Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 48,536,734 | 1,092,209 | 4,126,430 | Not specified |
Executive compensation was approved by a large majority, indicating strong shareholder support for management’s performance and alignment with shareholder interests.
Other Notable Corporate Information
- The Company’s common stock trades on The Nasdaq Global Select Market under the symbol CGEM.
- Cullinan Therapeutics, Inc. is incorporated in Delaware, with headquarters at One Main Street, Suite 1350, Cambridge, MA 02142.
- Mary Kay Fenton, Chief Financial Officer, signed the filing on behalf of the Company.
- Cullinan Therapeutics, Inc. is no longer classified as an Emerging Growth Company.
Potential Price-Sensitive Implications for Investors
- Leadership Stability: The re-election of directors and strong support for executive compensation may be interpreted as a mandate for current strategic direction, potentially reducing leadership risk and supporting share value.
- Audit Ratification: The decisive ratification of KPMG LLP may reassure investors about the reliability of Cullinan’s financial disclosures.
- No Shareholder Dissent: The lack of significant opposition on all proposals points to cohesive shareholder sentiment, which could positively influence market perceptions.
There were no extraordinary items, mergers, acquisitions, or other special matters presented at the meeting that would have an immediate or dramatic impact on the share price. However, the overall shareholder support for management and governance is a positive signal.
Disclaimer: This article summarizes key points from Cullinan Therapeutics, Inc.’s Form 8-K filed for its Annual Meeting of Stockholders held on June 16, 2026. This summary does not constitute investment advice. Investors should review the official filing and consult with their financial advisors before making any investment decisions. The information herein is provided for informational purposes only and may be subject to change.
